Black Rock Inc. In8 Bio, Inc. Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INAB
# of Institutions
13Shares Held
2.74MCall Options Held
0Put Options Held
0-
Alyeska Investment Group, L.P. Chicago, IL2.08MShares$4.68 Million0.0% of portfolio
-
Bios Capital Management, LP Fort Worth, TX287KShares$644,9940.83% of portfolio
-
State Street Corp Boston, MA88.7KShares$199,6780.0% of portfolio
-
Two Sigma Securities, LLC New York, NY34.3KShares$77,1270.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il29.5KShares$66,2620.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $55.1M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...